Overview

A Trial of HRS8179 on Brain Swelling After Large Hemispheric Infarction

Status:
Not yet recruiting
Trial end date:
2024-01-15
Target enrollment:
Participant gender:
Summary
The primary objective is to explore if HRS8179 could improve midline shift at 72 hours (or at time of decompressive craniectomy or comfort measures only, if earlier) in participants with large hemispheric infarction. The secondary objective is to explore if HRS8179 could improve acute neurologic status, functional outcomes, treatment requirements and safety.
Phase:
Phase 2
Details
Lead Sponsor:
Beijing Suncadia Pharmaceuticals Co., Ltd